-
Charles River To Buy WuXi For $1.6 Billion
Monday, April 26, 2010 - 5:36am | 145Charles River Laboratories (NYSE: CRL), the clinical research firm, will acquire China's WuXi Pharmaceuticals (NYSE: WX) for $1.6 billion in cash and stock. Massachusetts-based Charles River will offer $21.25 per WuXi ADR and each WuXi ADR will be exchanged for $11.25 in cash and $10 of Charles...
-
Theravance's Loss Widens - Analyst Blog
Thursday, April 22, 2010 - 10:30am | 777Theravance (THRX) reported first quarter fiscal 2010 loss per share of 35 cents, 7 cents more than the Zacks Consensus Estimate and worse than the loss of 29 cents in the year-ago period. Theravance earns revenues in the form of milestone payments from its partners including GlaxoSmithKline (GSK...
-
Top Stocks of Massachusetts
Tuesday, April 20, 2010 - 1:04pm | 854Massachusetts is the third most densely populated state with a per capita personal income that is the third highest in the country. The state economy is diversified and encompasses the financial, higher education, and high tech industries. Some interesting facts about Massachusetts follow: 1....
-
Jefferies & Company, Inc. Raises Price Target For Pharmaceutical Product Development, Inc. (PPDI)
Monday, April 19, 2010 - 1:10pm | 119Analysts at Jefferies & Company, Inc. have raised the price target for Pharmaceutical Product Development, Inc. (NASDAQ: PPDI) from $27.50 to $29.50 based on a higher 2011 EPS estimate for the company. According to analysts, the Eisai agreement announced at the Partnerships conference may be...
-
Benzinga’s Top Pre-Market Gainers (IMMU, POZN, ONXX, TASR, SQNM)
Monday, April 19, 2010 - 9:06am | 182Immunomedics, Inc (NASDAQ: IMMU) jumped 5.00% to $ $3.78 in the pre-market session. Immunomedics has developed a novel protein complex for the targeted delivery of small interfering ribonucleic acids (siRNAs) to several types of cancers. Pozen, Inc (NASDAQ: POZN) gained 2.74% to $10.50 in the pre-...
-
Cell Therapeutics Cuts Jobs - Analyst Blog
Friday, April 16, 2010 - 12:30pm | 382Cell Therapeutics (CTIC) recently reduced its workforce by 36 employees. The reduction in staff strength along with the elimination of other planned expenses is likely to result in savings of about $16 million in 2010. The company now expects operating expenses in 2010 to be approximately $60...
-
MEDTOX Scientific (MTOX) Earnings Match Estimates
Wednesday, April 14, 2010 - 8:58am | 97MEDTOX Scientific, Inc. (NASDAQ: MTOX) on Wednesday morning announced 1st quarter results in line with analyst expectations. MEDTOX Scientific reported 1st quarter earnings of 1 cent per share, down from 5 cents per share a year earlier. Although earnings were down for the 1st quarter, the company...
-
Bruker Corporation (BRKR) Could Be A Winner; Barron’s
Tuesday, April 13, 2010 - 4:20pm | 103According to a report by Barron’s, Bruker Corporation (NASDAQ: BRKR), a manufacturer of scientific instruments, could benefit from the rush to expand the scope of biological and material sciences. Over the last 12-months, shares of the Billerica, Massachusetts-based company have increased from $5....
-
Cell's Pixantrone Denied Approval - Analyst Blog
Friday, April 9, 2010 - 1:30pm | 471In a major setback, Cell Therapeutics (CTIC) has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for Pixuvri (pixantrone dimaleate). The company has been seeking approval for pixantrone for the treatment of relapsed or refractory aggressive non-Hodgkin’s...
-
Benzinga's After Hours Gainers (KEY, VANDA, NKTR)
Tuesday, April 6, 2010 - 6:07pm | 189Among the stocks that are moving in the after hours are KeyCorp (NYSE: KEY), Vanda Pharmaceuticals (NASDAQ: VNDA), and Nektar Therapeutics (NASDAQ: NKTR). Shares of KeyCorp (KEY) have gained 2.72% in the late trading session. This comes on top of a 3.80% gain during regular market hours. Volume in...
-
William Blair & Co. Outlook For Nektar Therapeutics (NKTR)
Tuesday, April 6, 2010 - 2:23pm | 193William Blair & Co. updated their outlook for Nektar Therapeutics (NASDAQ: NKTR) today in a research report. The analysts wrote that "given the significant 205% appreciation in shares of Nektar since our initiation on April 6, 2009, we are taking the opportunity to revisit our investment thesis...
-
Gainers and Losers On April 5
Tuesday, April 6, 2010 - 6:52am | 340Shares that made an impression with their moves in the US market yesterday are: Gainers Shares of National Dentex Corp (NASDAQ: NADX) soared 68% after the operator said that it is to be acquired by GDC Holdings Inc for $17 a share. Keryx Biopharmaceuticals Inc (NASDAQ: KERX) gained 22.3% after the...
-
Anchor BanCorp, Melco Crown: Midday Volume Plays (ABCW, SMMX, ACCL))
Monday, April 5, 2010 - 1:23pm | 168NEW YORK (TheStreet) -- Several stocks trading near $5 were moving on above-average volume during Monday's session. Anchor BanCorp Wisconsin (NASDAQ: ABCW) tumbled by 34 cents, or 30.1%, to 80 cents after the company said it was exploring strategic alternatives to build its capital position,...
-
CONSUMER BANKRUPTCIES HIGHEST SINCE 2005
Friday, April 2, 2010 - 7:15pm | 212As if today’s jump in the U6 unemployment rate wasn’t a sure enough sign of continuing weak consumers – the American Bankruptcy Institute is reporting that consumer bankruptcies in March jumped to their highest level since 2005. The consumer balance sheet is far from repaired. This recovery...
-
Leon Cooperman on the Prospects for M&A
Thursday, April 1, 2010 - 9:15am | 303Leon Cooperman of Omega Advisors is said to be the hardest-working man in the hedge fund game, boasting an 18 year track record of 16% annual returns versus the S&P 500's 10% according to Fortune Magazine. In a wide-ranging interview with Fortune, Cooperman makes the case that there is still...